plaque psoriasis
Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis
November 4, 2020Research and Development BMS, deucravacitinib, plaque psoriasis
Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …
FDA expands Stelara indication to cover paediatric plaque psoriasis
July 31, 2020Medical Communications, Sales and Marketing Janssen, Stelara, pharma, plaque psoriasis
Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …
Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says
June 15, 2020Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis
Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual …
UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis
October 17, 2019Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis
UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …
New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
April 30, 2019Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …
NICE recommends UCB’s Cimzia in severe plaque psoriasis
April 18, 2019Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …
Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis
October 22, 2018Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis
Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …
Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis
February 19, 2018Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis
Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …
NICE recommends plaque psoriasis contender for NHS use
August 8, 2017Manufacturing and Production, Sales and Marketing Almirall, NICE< Skilarence, drugs, life sciences, medicine, pharma, pharmaceuticals, plaque psoriasis, psoriasis
The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave …
FDA approves Lilly’s plaque psoriasis drug Taltz
March 23, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …
